Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.

Aogi K, Rai Y, Ito Y, Masuda N, Watanabe J, Horiguchi J, Tokudome T, Takashima S.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1427-33. doi: 10.1007/s00280-013-2140-y. Epub 2013 Mar 28.

PMID:
23536163
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN.

J Clin Oncol. 2007 Aug 10;25(23):3407-14. Epub 2007 Jul 2.

PMID:
17606974
[PubMed - indexed for MEDLINE]
3.

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.

Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E.

Clin Breast Cancer. 2008 Jun;8(3):234-41. doi: 10.3816/CBC.2008.n.026.

PMID:
18650153
[PubMed - indexed for MEDLINE]
4.

Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.

Wang J, Fan Y, Xu B.

Cancer Chemother Pharmacol. 2010 Aug;66(3):597-603. doi: 10.1007/s00280-010-1362-5. Epub 2010 May 21.

PMID:
20490795
[PubMed - indexed for MEDLINE]
5.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M.

J Clin Oncol. 2007 Aug 10;25(23):3399-406. Epub 2007 Jul 2.

PMID:
17606975
[PubMed - indexed for MEDLINE]
6.

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.

PMID:
18840366
[PubMed - indexed for MEDLINE]
7.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH.

J Clin Oncol. 2007 Nov 20;25(33):5210-7. Epub 2007 Oct 29.

PMID:
17968020
[PubMed - indexed for MEDLINE]
8.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.

Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH.

Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8.

PMID:
20454927
[PubMed - indexed for MEDLINE]
9.

Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer.

Seo HY, Lee HJ, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Lee ES, Kim YH, Kim JS, Seo JH.

Invest New Drugs. 2011 Apr;29(2):360-5. doi: 10.1007/s10637-009-9357-y. Epub 2009 Nov 27.

PMID:
19943080
[PubMed - indexed for MEDLINE]
10.

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.

Roché H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN.

Breast Cancer Res Treat. 2011 Feb;125(3):755-65. doi: 10.1007/s10549-010-1251-y. Epub 2010 Dec 3.

PMID:
21128114
[PubMed - indexed for MEDLINE]
11.

Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.

Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y.

J Manag Care Pharm. 2009 Jul-Aug;15(6):467-75.

PMID:
19610679
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.

PMID:
19669644
[PubMed - indexed for MEDLINE]
13.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Curé H.

J Clin Oncol. 2007 Aug 10;25(23):3415-20. Epub 2007 Jul 2.

PMID:
17606972
[PubMed - indexed for MEDLINE]
14.

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P.

J Clin Oncol. 2010 Jul 10;28(20):3256-63. doi: 10.1200/JCO.2009.24.4244. Epub 2010 Jun 7.

PMID:
20530276
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.

Rivera E.

Breast J. 2010 May-Jun;16(3):252-63. doi: 10.1111/j.1524-4741.2009.00896.x. Epub 2010 Apr 12. Review.

PMID:
20408828
[PubMed - indexed for MEDLINE]
16.

Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.

Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M.

J Clin Oncol. 2002 May 15;20(10):2551-8.

PMID:
12011135
[PubMed - indexed for MEDLINE]
17.

Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.

Valero V, Vrdoljak E, Xu B, Thomas E, Gómez H, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, Vahdat L, Mukhopadhyay P, Opatt D, Sparano JA.

Clin Breast Cancer. 2012 Aug;12(4):240-6. doi: 10.1016/j.clbc.2012.03.013. Epub 2012 Jun 2.

PMID:
22658378
[PubMed - indexed for MEDLINE]
18.

New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.

Pronzato P.

Drugs. 2008;68(2):139-46. Review.

PMID:
18197722
[PubMed - indexed for MEDLINE]
19.

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med. 2011;43(6):477-86. doi: 10.3109/07853890.2011.579151. Epub 2011 May 17. Review.

PMID:
21585248
[PubMed - indexed for MEDLINE]
20.

Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.

Fumoleau P, Cortés-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, Tubiana-Hulin M, Slabber CF, Caroff-Paraïso I, Alberts AS, Ben Ayed F.

Am J Clin Oncol. 2009 Aug;32(4):375-80. doi: 10.1097/COC.0b013e31818f2d2f.

PMID:
19487917
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk